Investing
Biotech firm Amyris files for bankruptcy in US
© Reuters.
(Reuters) – Biotech firm Amyris (NASDAQ:) Inc on Wednesday said it has filed for Chapter 11 bankruptcy in a U.S. court and is planning to sell its consumer brands to improve the company’s liquidity position.
Amyris said it has secured a $190 million financing commitment to support day-to-day operations, adding that its entities outside the U.S. are not included in the bankruptcy proceedings.
In a filing with the Delaware bankruptcy court, the company listed estimated assets in the range of $500 million to $1 billion and liabilities in the range of $1 billon to $10 billion.
“Restructuring is intended to improve the Company’s cost structure, capital structure, and liquidity position while streamlining Amyris’ business portfolio to focus on its core competencies in R&D…,” the company said.
In June, Amyris said it was cutting jobs to reduce costs and appointed Han Kieftenbeld as new interim CEO, following the resignation of John Melo.
Amyris had also initiated a “strategic transformation program” in June and secured a term loan facility of up to $50 million.
Read the full article here
-
Investing5 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Passive Income5 days ago
How to Create a Routine That Balances Rest and Business Success
-
Side Hustles6 days ago
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles3 days ago
A Macy’s Employee Made Accounting Errors Worth $132 Million
-
Passive Income6 days ago
Customers Want More Than Just a Product — Here’s How to Keep Up
-
Investing2 days ago
Factbox-How Trump can overhaul US financial regulators when he takes office By Reuters
-
Side Hustles7 days ago
MIT Gives Free Tuition For Families Earning $200,000 or Less
-
Side Hustles5 days ago
Gift the Power of Language Learning with This Limited-Time Price on Babbel